|
Dyno Therapeutics Inc, a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, announced the launch of two new adeno-associated virus (AAV) gene delivery capsids for central nervous system (CNS) and muscular delivery, alongside updated in vivo results for previously released capsids Dyno-yp2 (CNS) and Dyno-bn8 (muscle). The company also shared advances from its AI-powered platform that connects frontier AI agents and foundation models to patients to accelerate cost-effective development of genetic medicine. These updates were presented during the company’s Scientific Symposium at the 29th American Society of Gene & Cell Therapy Annual Meeting.
Efficient, selective gene delivery remains a core challenge in gene therapy, as many treatments require high doses that raise safety risks, drive up costs and limit who can access them. Trained on billions of in vivo non-human primate measurements, Dyno’s platform engineers AAV capsids optimized for selective delivery, liver detargeting, cross-species translatability and manufacturability.
“Each capsid we launch demonstrates the power of combining deep biological insight with massively parallel multiplexed in vivo experiments and state-of-the-art AI models for protein design, and these new capsids raise the bar again,” said Eric Kelsic, CEO and co-founder of Dyno. “Every year, partners now have more options and greater confidence in identifying a suitable gene delivery vector for their therapeutic program. This is how it should feel to be rapidly advancing the frontiers of genetic medicine.”
The following Dyno capsids were optimized and validated for in vivo delivery to cynomolgus monkey, the most relevant non-human primate (NHP) model for predicting translation potential for human therapeutics.
Dyno-9zh for cross-species CNS delivery, crossing the BBB via ALPL-binding.
Dyno-9zh is engineered for efficient blood-brain barrier (BBB) crossing and widespread CNS transduction following intravenous administration across humans, NHPs and mice, supporting its potential as a high-performing delivery option for neurological gene therapies.
Demonstrates exceptional cross-species performance, through head-to-head comparison across NHPs and mice and validated binding to human Alkaline Phosphatase, supporting human translatability.
Compared to TTM-027, delivers with comparable CNS transduction efficiency and liver detargeting in NHPs, and with ~2x higher CNS transduction in mice.
At a dose of 3×10¹³ vg/kg, broadly transduces NHP brain and spinal cord, with up to 50% of neurons transduced in premotor cortex.
Significantly lower liver biodistribution compared to AAV9 in both NHPs and mice.
Compatible with AAV9 production processes for scalable and cost-effective manufacturing.
|